Mov Disord Vol 34, Suppl 2 Archives - Page 10 of 217 - MDS Abstracts

2019 International Congress
Assessment of Caregiver Burden in Huntington’s disease
M. Yu, K. Tan, K. Koloms, D. Bega (Chicago, IL, USA)
Objective: We aim to identify and characterize caregiver burden among HD caregivers, to see what aspects of HD caregiving are associated with the greatest burden…
2019 International Congress
Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients
C. Cattaneo, E. Bonizzoni, C. Keywood (Milan, Italy)
Objective: To evaluate the clinical effects of safinamide, administered as add-on therapy to levodopa in fluctuating PD patients, on symptoms severity and daily living. Background:…
2019 International Congress
Switching entacapone ‘non-responders’ to open-label opicapone: change in absolute OFF-time following the 1-year extension BIPARK-I study
J. Ferreira, A. Lees, W. Poewe, O. Rascol, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)
Objective: To evaluate the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) ‘non-responders’ patients who switched from placebo (PLC) or entacapone (ENT) to OPC…
2019 International Congress
The Effect of Gocovri on Motor Aspects of Experiences of Daily Living: Analyses of MDS-UPDRS Part II Data from a Phase 3 Program
R. Hauser, D. Kremens, D. Chernick, R. Patni, J. Hubble (Tampa, FL, USA)
Objective: To assess the impact of Gocovri® (amantadine) extended release capsules on motor aspects of experiences of daily living in PD patients. Background: Gocovri is…
2019 International Congress
Pharmacological effect of adenosine A2A receptor antagonist for levodopa-induced dyskinesia associated with cellular energy homeostasis
NAO. Kanzato (Okinawa, Japan)
Objective: To evaluate the Levodopa induced dyskinesia (LID) in the clinical view point of autophagy and cellular energy homeostasis, and the pharmacological effect of adenosine…
2019 International Congress
Use digital sensor and deep learning to evaluate motor performance in the D1PAM (LY3154207) phase 1B Parkinson’s disease clinical trial
Y. Li, Y. Guan, J. Wang, A. Calvin, J. Kyle, B. Miller (Indianapolis, IN, USA)
Objective: This study aims to test the feasibility of using digital tools to evaluate motor performance in a Parkinson’s disease clinical trial. Background: Modern smartphones…
2019 International Congress
Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson’s Disease.
M. Meloni, M. Figorilli, M. Carta, L. Tamburrino, A. Cannas, M. Fantini, G. Defazio, M. Puligheddu (Cagliari, Italy)
Objective: To evaluate the efficacy of the 5-HTP on RBD status in patients with Parkinson's disease (PD). Background: REM sleep behavior disorder (RBD) is reported…
2019 International Congress
The Efficacy and Safety of Gocovri Based on Age: Special Population Analyses of a Phase 3 Study Program
R. Pahwa, C. Tanner, L. Zhang, R. Johnson, C. Leroue, R. Patni (Kansas City, KS, USA)
Objective: To assess patient outcomes and adverse events in Parkinson’s disease (PD) patients treated with Gocovri® (amantadine) extended release capsules at bedtime for dyskinesia, by…
2019 International Congress
Motor assessments in HD clinical trials: Q-Motor versus the UHDRS-TMS – what did we learn from recent studies?
R. Reilmann, R. Schubert, P. Barallon, P. Pracht, B. Habbel (Muenster, Germany)
Objective: To review the performance of UHDRS-TMS and Q-Motor quantitative motor measures in recent placebo-controlled clinical trials. Background: The UHDRS-TMS has widely been used to…
2019 International Congress
Parkinson’s disease and intermittent hypoxia training: beneficial or harmful?
M. Sharifi-Bonab, J. Sesink, B. Bloem, D. Devos, J. Deguil, C. Moreau (Nijmegen, Netherlands)
Objective: To systematically review the scientific evidence for beneficial or harmful effects of intermittent hypoxia that were used in Parkinson’s disease (PD) in clinical and…